Clarus Therapeutics Holdings, Inc. (CRXT) A – Z New Updates.

Get the latest Clarus Therapeutics Holdings, Inc. Stock updates for upcoming Days, Weeks and Long-Term Clarus Therapeutics Holdings, Inc. Price Prediction for upcoming years 2023, 2024, and 2025 to 2030.

Stock Market investments requires careful consideration and analysis of various factors, including price predictions and the latest updates surrounding a particular stock. In this blog post, we will dive into CRXT, a prominent stock, and provide an in-depth analysis of its price prediction and the most recent updates. Let’s explore the potential of CRXT and understand the factors influencing its performance.

CRXT Barchart

By understanding the key drivers behind CRXT’s performance, investors can make more informed decisions about their investment strategies.

CRXT Stock Price Prediction 2023

“According to our current CRXT stock forecast, the value of Clarus Therapeutics Holdings, Inc. shares will rise by 0.00% and reach $ 0.047500 per share by June 19, 2023. According to our technical indicators, the current sentiment is Neutral while the Fear & Greed Index is showing 39 (Fear).”

Predicted by

CRXT Stock Price Prediction 2024

For the year 2024, it’s not very much sure to invest in CRXT stock and that too for  1-year term. Most of the stock websites have mixed predictions, but I suggest to not to invest in this stock if you’re not planning for long term secondary stock. The real time quote is equal to 0.03 USD, but if you’ve already invested then it might can devalue in future. As per the research reports, the price will be down by 50% by the coming year and the expected price will be around 0.13 USD.

Prediction credits to and

CRXT Stock Price Prediction 2025

The stock prediction for year 2025 of The Clarus Therapeutics Holdings Inc. is around $0.0082. It can be assumed that CRXT stock can grow on consistent levels and has pretty less chances to go down as we have seen its consistent growth in the least 8 years. This can be a representation that the CRXT stock can grow its price by 80%.

Prediction credits to

CRXT Stock Price Prediction 2026

According to the latest prediction done by for CRXT Stock, the shares in June 2026 might b 0.00. According to them , there’s a possible expected monthly volatility of around 27.250%.

Predicted by

All About Clarus Therapeutics Inc.

Clarus was founded by Dr. Robert Dudley, chairman, CEO and president who developed an oral testosterone replacement therapy (TRT) for appropriate men with testosterone deficiency.  Dr. Dudley had previously co-invented and launched AndroGel®, the most successful TRT product to date, worldwide, but was keenly aware of the need for a safe and effective oral TRT for the approximately 2,000,000 men currently on testosterone therapy in the United States

The Northbrook, Illinoisbased biopharmaceutical business Clarus Therapeutics specializes in the creation and marketing of prescription medication treatments based on androgens. CLR-610, brand exclusive oral testosterone medication for the treatment of low testosterone in men, is Clarus’ flagship product. The market for oral testosterone replacement therapy, CLR-610, is currently dominated by gels.

Blue Water Acquisition Corp. (NASDAQ: BLUW) (“Blue Water”), special purpose acquisition company (SPAC), and Clarus Therapeutics Inc. (“Clarus”), pharmaceutical company committed to addressing unmet medical needs by developed androgen and metabolic therapies for men and women, today announced binding business combination agreement that will turn Clarus into publicly traded company. On fully diluted basis, the acquisition values Clarus at $379 million, assuming no redemptions by Blue Water stockholders.

Investment Highlights of CRXT.

Clarus Therapeutics Inc, (CRXT Sock)

  • Clarus is valued at $379 million in the SPAC transaction, assuming no redemptions by Blue Water shares.
  • Following the announcement of this transaction, existing Clarus shareholders, led by H. I. G. Capital, will invest an additional $25 million in Clarus, whose investment will convert into shares of the post-merger company’s common stock at $10.00 per share.
  • The sale proceeds will be spent in JATENZO’s expansion activities, including DTC advertising, as well as Clarus’ R&D pipeline.
  • Clarus’ financial advisor was Truist Securities, and its capital markets advisor was Needham Company.
  • Maxim Group LLC acted as financial advisor to Blue Water Acquisition Corp.
  • Cantor Fitzgerald & Co. and Oppenheimer & Co., Inc. acted as capital markets advisors to Blue Water Acquisition Corp.


With the immanent commercial launch of its Jatenzo testosterone capsules, Clarus Therapeutics stock could be ready to rise.
Clarus Therapeutics (CRXT) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week.
Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) has implemented a 40% reduction in staff as it evaluates strategic alternatives and terminates certain research and development activities.
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company.
Today, meme penny stocks and blue chips got a major bump. By EOD on March 28th, shares of AMC Entertainment Holdings Inc. (NYSE: AMC) and…

2 thoughts on “Clarus Therapeutics Holdings, Inc. (CRXT) A – Z New Updates.”

Leave a comment